Hemogenyx Pharmaceuticals PLC Presentation at H.C. Wainwright Global Conference
September 01 2022 - 3:45AM
RNS Non-Regulatory
TIDMHEMO
Hemogenyx Pharmaceuticals PLC
01 September 2022
1 September 2022
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Presentation at H.C. Wainwright Global Investment Conference
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical
group developing new therapies and treatments for blood diseases,
is pleased to announce its participation in the H.C. Wainwright
24th Annual Global Investment Conference to be held on September
12-14, 2022, in New York City . The Company will be featured as a
presenting company. The conference will be hosted both in person as
well as virtually under a hybrid model.
As part of the Company's presentation, Dr Vladislav Sandler, CEO
of Hemogenyx Pharmaceuticals, will provide an overview of the
Company's business, product candidates and their progression toward
clinical trials.
The conference will feature corporate presentations, panels, and
one-on-one investor meetings. Dr Sandler's presentation will be
accessible using a webcast link for registered conference
participants.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx
Pharmaceuticals, commented: "Our presentation at the H.C.
Wainwright 24th Annual Global Investment Conference provides the
Company with a great opportunity to inform the investment community
about our achievements and increase the Company's visibility
globally. It also allows us to further establish Hemogenyx
Pharmaceuticals as a leader in the field of the development of
medicines for treatment of blood and autoimmune diseases."
Enquiries:
Hemogenyx Pharmaceuticals plc https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive
Officer & Co-Founder headquarters@hemogenyx.com
Peter Redmond, Director peter.redmond@hemogenyx.com
Tel: +44 (0)20 3470
SP Angel Corporate Finance LLP 0470
Matthew Johnson, Vadim Alexandre,
Adam Cowl
Tel: +44 (0)20 7469
Peterhouse Capital Limited 0930
Lucy Williams, Duncan Vasey, Charles
Goodfellow
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:
HEMO) headquartered in London, with its US operating subsidiaries,
Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New
York City at its state-of-the-art research facility.
The Company is a pre-clinical stage biopharmaceutical group
developing new medicines and treatments to treat blood and
autoimmune disease and to bring the curative power of bone marrow
transplantation to a greater number of patients suffering from
otherwise incurable life-threatening diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary
product candidates, as well as a platform technology that it uses
as an engine for novel product development.
For more than 50 years, bone marrow transplantation has been
used to save the lives of patients suffering from blood diseases.
The risks of toxicity and death that are associated with bone
marrow transplantation, however, have meant that the procedure is
restricted to use only as a last resort. The Company's technology
has the potential to enable many more patients suffering from
devastating blood diseases such as leukemia and lymphoma, as well
as severe autoimmune diseases such as multiple sclerosis, aplastic
anemia and systemic lupus erythematosus (Lupus), to benefit from
bone marrow transplantation.
About H.C. Wainwright & Co.
H.C. Wainwright is a full--service investment bank dedicated to
providing corporate finance, strategic advisory and related
services to public and private companies across multiple sectors
and regions. H.C. Wainwright & Co. also provides research and
sales and trading services to institutional investors. According to
Sagient Research Systems, H.C. Wainwright's team is ranked as the
#1 Placement Agent in terms of aggregate CMPO (confidentially
marketed public offering), RD (registered direct offering) and PIPE
(private investment in public equity) executed cumulatively since
1998.
For more information visit H.C. Wainwright & Co. on the web
at www.hcwco.com.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEAXNFELAAEEA
(END) Dow Jones Newswires
September 01, 2022 03:45 ET (07:45 GMT)
Silver Falcon (LSE:SILF)
Historical Stock Chart
From Apr 2024 to May 2024
Silver Falcon (LSE:SILF)
Historical Stock Chart
From May 2023 to May 2024